...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Annals of Gastroenterological Surgery >History and emerging trends in chemotherapy for gastric cancer
【24h】

History and emerging trends in chemotherapy for gastric cancer

机译：胃癌化疗中的历史与新兴趋势

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Chemotherapy is indispensable for gastric cancer. For unresectable and/or recurrent gastric cancer, first-line chemotherapy consists of multidrug regimens including oral 5-FU agents such as S1/Xeloda and platinum preparations, as well as Trastuzumab, which is effective in HER2-positive cases. Second- and third-line chemotherapy regimens include taxanes, Ramucirumab (R-mab), and Nivolumab (N-mab), which have different mechanisms of action from first-line chemotherapy. R-mab is molecularly targeted to vascular endothelial growth factor receptor 2 in the host cells, but its indication is not conditional. For resectable gastric cancer, in Eastern countries, postoperative adjuvant chemotherapy has been successful, including S1, Docetaxel/S1 (DS), and Xeloda/Oxaliplatin (Xelox) regimens, whereas, in Western countries, the 5-FU/Leucovorin/Oxaliplatin/Docetaxel (FLOT) regimen was recently shown to be effective in the perioperative chemotherapy setting. Most recently, however, in Eastern countries, perioperative SOX was demonstrated to be effective in specific advanced gastric cancer. For stage IV gastric cancer, new therapeutic strategies have been proposed such as neoadjuvant chemotherapy and conversion surgery, and cures can be conditionally obtained. Recent genomic understanding of gastric cancer proposed a diversity of molecular targets by molecular profiling. Such optimized chemotherapy regimens, according to the specific clinical situations, have been rigorously established for the best survival of advanced gastric cancer.
机译：化学疗法对于胃癌不可或缺。对于不可切除和/或复发性胃癌，一线化疗包括多药中规制方案，包括口服5-FU试剂，如S1 / Xeloda和铂制剂，以及曲妥珠单抗，其在HER2阳性病例中有效。第二和第三线化疗方案包括紫杉烷，Ramucirumab（R-MAB）和Nivolumab（N-MAB），其具有从一线化疗的不同作用机制。 R-MAb分子靶向宿主细胞中的血管内皮生长因子受体2，但其指示不是条件的。对于可重型的胃癌，在东方国家，术后辅助化疗已经成功，包括S1，Docetaxel / S1（DS）和Xeloda / Oxaliplatin（Xelox）方案，而在西方国家，5-Fu / Leucovorin / Oxaliplatin /最近显示Docetaxel（Flot）方案在围手术期化疗环境中有效。然而，最近，在东方国家，围手术期Sox被证明在特定的晚期胃癌中是有效的。对于第四阶段胃癌，已经提出了新的治疗策略，例如Neoadjuvant化疗和转化手术，并且可以有条件地获得治疗。最近对胃癌的基因组理解提出了分子剖面的多样性分子靶标。根据具体的临床情况，这种优化的化疗方案已经严格地建立了晚期胃癌的最佳存活。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号